



October 6, 2022

BSE Limited

Department of Corporate Services,
P. J. Towers,
Dalal Street,
MUMBAI - 400 001.

✓ **National Stock Exchange of India Limited**

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
Mumbai - 400 051.

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and
Disclosure Requirements) Regulations, 2015 (Listing Regulations).**

We are pleased to enclose a Press Release as regards, appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer of the Company.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

**Rajvardhan
Vishnu Satam**

Digitally signed by Rajvardhan Vishnu Satam
DN: c=IN, st=Maharashtra,
2.5.4.20=c19d8ef961d9fa59e973a093a4d3924b2532eb2f496ea7e2abcf74
700f5375b7, postalCode=400104, street=2404, SEJAL TOWER, SEJAL
PARK LINK ROAD, GOREGAON WEST, Mumbai, Mortal
Nagar, Borivali, Mumbai Suburban,
pseudonym=9a4b7cd219ea516ad56e6d651dcbbe5b, title=0191,
serialNumber=df8ebe60a88c796663c738ea25bfa0b475d195f726cdeb67a2
ff09c4242771b2a, o=Personal, cn=Rajvardhan Vishnu Satam
Date: 2022.10.06 21:43:51 +05'30'

**R. V. SATAM
COMPANY SECRETARY
(ACS - 11973)**

Encl: a/a

Lupin Appoints Dr. Shahin Fesharaki as Global Chief Scientific Officer

Mumbai, Baltimore, October 6, 2022: Global pharma major Lupin Limited (Lupin) today announced the appointment of Dr. Shahin Fesharaki as Global Chief Scientific Officer. Dr. Fesharaki will be responsible for Lupin's global research and development efforts across branded, generics and specialty products.

Commenting on the appointment, **Vinita Gupta, CEO and Nilesh Gupta, MD, Lupin** said, "We are very pleased to welcome Shahin to our leadership team. Shahin's exceptional track record in delivering brands and generics across developed and emerging markets will be valuable to us as we accelerate our evolution into complex generics and specialty while driving growth across all our major markets.

With nearly 30 years' experience in drug development in leading global pharmaceutical companies, Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals. Prior to that Dr. Fesharaki held various leadership positions in Teva, Allergan/Actavis, Watson Pharmaceuticals and Apotex.

Dr. Fesharaki has extensive development experience in both generic and branded pharmaceuticals across a broad range of technologies and dosage forms.

About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue on research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit www.lupin.com for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal>

LinkedIn : <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

For further information or queries please contact –

Shweta Munjal

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Vice President & Global Head – Corporate Communications

Email: shwetamunjal@lupin.com